Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...

Fractyl Health is deprioritizing a type 2 diabetes trial in favor of a pivotal study of its endoscopy treatment Revita and ...

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...

While the former Biden administration showcased the Inflation Reduction Act as a key victory in the fight over high drug ...

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

Blackstone joins other big investors such as ARCH Venture Partners and Bain Capital Life Sciences in pumping billions of ...

The layoffs will allow Ironwood to dedicate more resources to pushing its lead molecule apraglutide through a Phase III trial ...

Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while ...

ImmunityBio will part with 10 employees this quarter. Last fall, it cut 31 employees. The moves come as the biotech works to advance Anktiva in non-small cell lung cancer.

Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and ...

CAR T–focused biotech Cargo Therapeutics surprised and disappointed analysts when it announced that it would discontinue a ...

The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex's non-opioid treatment Journavx.